Incorporating Information from Completed Trials in Future Trial Planning
暂无分享,去创建一个
[1] Kerrie Mengersen,et al. Elicitation by design in ecology: using expert opinion to inform priors for Bayesian statistical models. , 2009, Ecology.
[2] W Ewy,et al. Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.
[3] D. Spiegelhalter,et al. Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .
[4] Anthony O'Hagan,et al. Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.
[5] Anthony O'Hagan,et al. Assurance in clinical trial design , 2005 .
[6] M. Kynn. The ‘heuristics and biases’ bias in expert elicitation , 2007 .
[7] Bradley P Carlin,et al. Practical Bayesian Design and Analysis for Drug and Device Clinical Trials , 2007, Journal of biopharmaceutical statistics.
[8] J Cornfield,et al. The Bayesian outlook and its application. , 1969, Biometrics.
[9] Modeling and Simulation to Support Dose Selection and Clinical Development of SC‐75416, a Selective COX‐2 Inhibitor for the Treatment of Acute and Chronic Pain , 2008, Clinical pharmacology and therapeutics.
[10] Simon Day,et al. Structured approach to the elicitation of expert beliefs for a Bayesian‐designed clinical trial: a case study , 2013, Pharmaceutical statistics.
[11] Jeremy E. Oakley,et al. Uncertain Judgements: Eliciting Experts' Probabilities , 2006 .
[12] David J. Lunn,et al. The BUGS Book: A Practical Introduction to Bayesian Analysis , 2013 .
[13] N Benson,et al. Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development , 2013, Clinical pharmacology and therapeutics.
[14] Phil Woodward,et al. Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study , 2015, Pharmaceutical statistics.